Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for Advanced Cell and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective small-molecule inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, exhibiting IC₅₀ values of ~140 nM and a >200-fold selectivity over other kinases (APExBIO). This compound disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and is soluble at ≥52.9 mg/mL in water and ≥111.2 mg/mL in DMSO. Y-27632 is widely adopted for enhancing stem cell viability, suppressing tumor invasion, and enabling reproducible cytoskeletal studies (Ni et al., 2022). It is a validated research tool for both in vitro and in vivo models, with precise handling parameters for stock solution preparation and stability (First-Strand-cDNA.com).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases critical for cytoskeletal organization and cellular contractility. They regulate actin stress fiber formation, cell adhesion, migration, and cytokinesis. Dysregulation of Rho/ROCK signaling is implicated in cancer metastasis, fibrosis, and neurodegenerative disease. Selective inhibition of these kinases enables precise dissection of their roles in cell proliferation, stem cell maintenance, and tumor invasion (Mouse-IL.com). Y-27632 dihydrochloride, supplied by APExBIO, serves as a gold-standard tool for probing ROCK-dependent cellular events.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively inhibits the ATP-binding site of ROCK1 and ROCK2. It exhibits an IC₅₀ of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2, with over 200-fold selectivity against protein kinases including PKC, MLCK, and PAK (APExBIO product datasheet). Inhibition of ROCK activity leads to decreased phosphorylation of downstream targets such as myosin light chain (MLC), resulting in disruption of actin-myosin contractility. This mechanism abrogates Rho-mediated formation of stress fibers and focal adhesions, interferes with G1/S cell cycle progression, and impairs cytokinesis. In stem cells, Y-27632 prevents apoptosis post-dissociation and enhances clonal survival (Ni et al., 2022).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a Ki of 300 nM in enzymatic assays (APExBIO).
• It displays over 200-fold selectivity for ROCK1/2 over related kinases such as PKC and MLCK, minimizing off-target effects (GTP-Binding Protein Fragment).
• In prostatic smooth muscle cells, Y-27632 reduces cell proliferation in a concentration-dependent manner (in vitro) (Dyngo-4A.com).
• In mouse models, Y-27632 diminishes tumor invasion and metastasis in vivo (Ni et al., 2022).
• It is routinely used to enhance survival of dissociated human iPSCs and ESCs, supporting robust colony formation after single-cell passaging (Ni et al., 2022).

This article provides updated in vitro and in vivo usage parameters compared to prior reviews, which focused mainly on cytoskeletal effects.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is applied in diverse research contexts:

• Stem cell research: Enhances iPSC/ESC survival post-dissociation; enables single-cell cloning (Ni et al., 2022).
• Cancer biology: Suppresses tumor invasion and metastasis in mouse xenograft models (Dyngo-4A.com).
• Cytoskeletal studies: Disrupts stress fiber formation and focal adhesion assembly (Mouse-IL.com).
• Cell proliferation/cell cycle assays: Modulates G1/S transition and inhibits cytokinesis (First-Strand-cDNA.com).

Compared to Precision Modulation of Rho/ROCK Signaling, this article details specific solubility and handling parameters for experimental reproducibility.

Common Pitfalls or Misconceptions

• Y-27632 dihydrochloride does not inhibit all Rho pathway components—its selectivity is limited to ROCK1/2, not upstream GTPases (e.g., RhoA).
• It is not a substitute for broad-spectrum kinase inhibition; off-target activity is minimal only at recommended concentrations.
• Long-term storage of prepared solutions (>1 month) is discouraged due to potential degradation (APExBIO).
• Y-27632 does not inherently induce stemness or pluripotency; it supports survival by reducing apoptosis.
• It is not effective in models where ROCK-independent mechanisms drive cytoskeletal reorganization.

Workflow Integration & Parameters

Y-27632 dihydrochloride (APExBIO A3008) is supplied as a solid and should be stored desiccated at 4°C or below. For solution preparation, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Solubility may be enhanced using a 37°C water bath or ultrasonic treatment. Stock solutions are stable for several months at below –20°C. Avoid repeated freeze-thaw cycles and prolonged storage of working dilutions. Typical working concentrations range from 1–10 μM for stem cell and cytoskeletal assays (APExBIO). For experimental design, include controls for vehicle (DMSO or ethanol) and titrate concentrations to minimize off-target effects.

For advanced troubleshooting and protocol guidance, see this resource, which details APExBIO’s batch control and reproducibility standards. This article extends these discussions by providing explicit storage and solubility recommendations based on product documentation and recent peer-reviewed use cases.

Conclusion & Outlook

Y-27632 dihydrochloride remains a cornerstone for dissecting the Rho/ROCK signaling pathway in cell biology, regenerative medicine, and cancer research. Its unmatched selectivity and robust solubility profile enable reproducible manipulation of cytoskeletal processes and stem cell viability. Future research may leverage Y-27632 in novel 3D organoid systems and patient-derived iPSC models to further elucidate disease mechanisms and accelerate drug screening. For detailed product specifications and ordering, see the APExBIO Y-27632 dihydrochloride product page.